Drugs used in tuberculosis and leprosy

Side Effects of Drugs Annual

Volumn 31, Issue C, 2009, Pages 495-505

  Swaminathan, Soumya ^a   Rekha, V V Banu ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77954707621     PISSN: 03786080     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0378-6080(09)03130-4     Document Type: Article

References (44)

1. Yew WW, Leung CC. Antituberculosis drugs and hepatotoxicity. Respirology 2006;11: 699-707.
2. Ijaz K, Jereb JA, Lambert LA, Bower WA, Spradling PR, McElroy PD, Iademarco MF, Navin TR, Castro KG. Severe or fatal liver injury in 50 patients in the United States taking rifampin and pyrazinamide for latent tuberculosis infection. Clin Infect Dis 2006;42: 346-55.
3. Schechter M, Zajdenverg R, Falco G, Barnes G L, Faulhaber JC, Coberly JS, Moore RD, Chaisson RE. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. Am J Respir Crit Care Med 2006;173:922-6.
4. Page KR, Sifakis F, Montes de Oca R, Cronin WA, Doherty MC, Federline L, Bur S, Walsh T, Karney W, Milman J, Baruch N, Adelakun A, Dorman SE. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med 2006;166:1863-70.
5. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloquin CA, Gordin FM, Nunes D, Strader DB, Bernardo J, Venkataramanan R, Sterling TR An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006;174:935-52.
6. Idilman R, Ersoz S, Coban S, Kumbasar O, Bozkaya H. Antituberculous therapy-induced fulminant hepatic failure: successful treatment with liver transplantation and nonstandard antituberculous therapy. Liver Transplant 2006;12(9):1427-30.
7. Gülbay BE, Gürkan OU, Yildiz OA, Onen ZP, Erkekol FO, Baççioglu A, Acican T. Side effects due to primary antituberculosis drugs during the initial phase of therapy in [1149] hospitalized patients for tuberculosis. Respir Med 2006;100:1834-2.
8. Wertheim MS, Males JJ, Cook SD, Tole DM. Dapsone induced haemolytic anaemia in patients treated for ocular cicatricial pemphigoid. Br J Ophthalmol 2006;90:516.
9. Schiff DE, Roberts WD, Sue Y-J. Methe-moglobinemia associated with dapsone ther apy in a child with pneumonia and chronic immune thrombocytopenic purpura. J Pediatr Hematol Oncol 2006;28:395-8.
10. Abidi MH, Kozlowski JR, Ibrahim RB, Peres E. The sulfone syndrome secondary to dapsone prophylaxis in a patient undergoing unrelated hematopoietic stem cell transplan tation. Hematol Oncol 2006;24:164-5.
11. Choi WI, June Jeon Y, Kwon KY, Ko SM, Keum DY, Kwon Park C. Acute lung injury caused by ethambutol. Respir Med Extra 2006;2:55-7.
12. Ikeda A, Ikeda T, Ikeda N, Kawakami Y, Mimura O. Leber's hereditary optic neuropathy precipitated by ethambutol. Jpn J Ophthalmol 2006;50:280-3.
13. Kardon RH, Morrisey MC, Lee AG. Abnormal multifocal electroretinogram (mfERG) in ethambutol toxicity. Semin Ophthalmol 2006;21(4):215-22.
14. Abraham S, Mitchell A, Cope A. Antituberculous therapy-induced crystal arthropathy. Rheumatology 2006;45:1173-4.
15. Tibussek D, Mayatepek E, Distelmaier F, Rosenbaum T. Status epilepticus due to attempted suicide with isoniazid. Eur J Pediatr 2006;165(2):136-7.
16. Ambrosetti M, Ferrarese M, Codecasa LR, Besozzi G, Sarassi P, Viggiani P, Migliori GB. Incidence of venous thromboembolism in tuberculosis patients. Respiration 2006; 73:396.
17. Azad A, Connelly N. Case of rifampicin-induced acute generalized exanthematous pustulosis. Int Med J 2006;36:619-20.
18. Buergin S, Scherer K, Hausermann P, Bircher AJ. Immediate hypersensitivity to rifampicin in 3 patients: diagnostic proce dures and induction of clinical tolerance. Int Arch Allergy Immunol 2006;140:20-6.
19. Burger DM, Agarwala S, Child M, Been-Tiktak A, Wang Y, Bertz R. Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers. Antimicrob Agents Chemother 2006;50(10):3336-42.
20. Naesens M, Kuypers DRJ, Streit F, Armstrong VW, Oellerich M, Verbeke K, Vanrenterghem Y. Rifampin induces altera tions in mycophenolic acid glucuronidation and elimination: implications for drug exposure in renal allograft recipients. Clin Pharmacol Ther 2006;80:509-21.
21. Manosuthi W, Sungkanuparph S, Thakkinstian A, Rattanasiri S, Chaovavanich A, Prasithsirikul W, Likanonsakul S, Ruxrungtham K. Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifam picin. Clin Infect Dis 2006;43:253-5.
22. Ramachandran G, Hemanthkumar AK, Rajasekaran S, Padmapriyadarsini C, Narendran G, Sukumar B, Sathishnarayan S, Raja K, Kumaraswami V, Swaminathan S. Increasing nevirapine dose can overcome reduced bio availability due to rifampicin coadministration. J Acquir Immune Defic Syndr 2006;42(1):36-41.
23. Prasad B, Bhutani H, Singh S. Study of the interaction between rifapentine and isonia zid under acid conditions. J Pharm Biomed Anal 2006;41(4):1438-41.
24. Zhang Y, Post-Martens K, Denkin S. New drug candidates and therapeutic targets for tuberculosis therapy. Drug Discov Today 2006;11(1-2):21-7.
25. Lamichhane G, Zignol M, Blades NJ, Geiman DE, Dougherty A, Grosset J, Broman KW, Bishai WR. A postgenomic method for predicting essential genes at subsaturation levels of mutagenesis: appli cation to Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2003;100:7213-8.
26. Sassetti CM, Rubin EJ. Genetic requirements for mycobacterial survival during infection. Proc Natl Acad Sci USA 2003;100:1298-9.
27. McKinney JD, Höner zu Bentrup K, Muñoz-Elías EJ, Miczak A, Chen B, Chan WT, Swenson D, Sacchettini JC, Jacobs Jr WR, Russell DG. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 2000;406 (6797):735-8.
28. Glickman MS, Cox JS, Jacobs WR. A novel mycolic acid cyclopropane synthetase is required for cording, persistence, and virulence of Mycobacterium tuberculosis. Mol Cell 2000;5:717-27.
29. Dahl JL, Kraus CN, Boshoff HI, Doan B, Foley K, Avarbock D, Kaplan G, Mizrahi V, Rubin H, Barry 3rd CE. The role of RelMtb-mediated adaptation to stationary phase in long-term persistence of Mycobac terium tuberculosis in mice. Proc Natl Acad Sci USA 2003;100(17):10026-31.
30. Dong PH, Guinn KM, Harrell MI, Liao R, Voskuil MI, Tompa M, Schoolnik GK, Sherman DR. Rv3133c/dosR is a transcrip tion factor that mediates the hypoxic response of Mycobacterium tuberculosis. Mol Microbiol 2003;48:833-3.
31. Zhang Y. The magic bullets and tuberculosis drug targets. Annu Rev Pharmacol Toxicol 2005;45:529-64.
32. Mitchison DA. The search for new sterilizing anti-tuberculosis drugs. Front Biosci 2004;9:1059-72.
33. Spigelman MK. New tuberculosis therapeutics: a growing pipeline. J Infect Dis 2007;196:S28-34.
34. Andries K, Verhasselt P, Guillemont J, Göhlmann HWH, Neefs JM, Winkler H, Van Gestel J. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005;307:223-7.
35. Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, Langhorne MH, Anderson SW, Towell JA, Yuan Y, McMurray DN, Kreiswirth BN, Barry CE, Baker WR. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000;405:962-6.
36. Tyagi S, Nuermberger E, Yoshimatsu T, Williams K, Rosenthal I, Lounis N, Bishai W, Grosset J. Bactericidal activity of the nitroimidazopyran PA-824 in the murine model of tuberculosis. Antimicrob Agents Chemother 2005;49(6):2289-93.
37. Matsumoto M, Hshizume H, Tomishige T, Kawasaki M. In vitro and in vivo efficacy of novel antituberculous candidate OPC-67683 [abstract F-1462]. In: Program and abstracts of the 45th interscience conference on anti microbial agents and chemotherapy (Washington, DC). Washington, DC: Amer ican Society for Microbiology; 2005. p. 204.
38. Sasaki H, Haraguchi Y, Itotani M, Kuroda H, Hashizume H, Tomishige T, Kawasaki M, Matsumoto M, Komatsu M, Tsubouchi H. Synthesis and antituberculo-sis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b] oxazoles. J Med Chem 2006;49(26):7854-60.
39. Nuermberger EL, Yoshimatsu T, Tyagi S, O'Brien RJ, Vernon AN, Chaisson RE, Bishai WR, Grosset JH. Moxifloxacin-containing regimen greatly reduces time to culture con version in murine tuberculosis. Am J Respir Crit Care Med 2004;169:421-6.
40. Nuermberger EL, Yoshimatsu T, Tyagi S, Williams K, Rosenthal I, O'Brien RJ, Vernon AA, Chaisson RE, Bishai WR, Grosset JH. Moxifloxacin-containing regi mens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med 2004;170:1131-4.
41. Pletz MW, Roux AD, Roth A, Neumann KH, Mauch H, Lode H. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrob Agents Chemother 2004;48:780-2.
42. Burman WJ, Goldberg S, Johnson JL, Muzanye G, Engle M, Mosher AW, Choudhri S, Daley CL, Munsiff SS, Zhao Z, Vernon A, Chaisson RE. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006;174(3):331-8.
43. Sinha RK, Arora SK, Sinha N, Modak VM. In vivo activity of LL4858 against Myco-bacterium tuberculosis [abstract F-1116]. In: Program and abstracts of the 44th interscience conference on antimicrobial agents and chemotherapy (Washington, DC). Washington, DC: American Society for Microbiology; 2004. p. 212.
44. Jia L, Tomaszewski JE, Hanrahan C, Coward L, Noker P, Gorman G, Nikonenko B, Protopopova M. Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug. Br J Pharmacol 2005;144(1):80-7.